Radiopharm Theranostics announced the appointment of Hester Larkin to its Board as a Non-Executive Director. Ms Larkin will commence the role on February 3, 2022, after a 30-year career spanning both pharmaceuticals and nuclear medicine across Europe, Middle East & Africa, including over 12 years of experience in senior leadership roles in the industry. She brings a proven track record of delivering significant corporate revenues and earnings and leading successful product launches of proprietary pharmaceuticals and imaging agents in oncology, cardiology, neurology and HIV.

Ms Larkin is currently Managing Director of Hester Larkin Associates Consulting where she provides consulting services to diagnostic imaging, pharmaceutical and biotech companies lending her expertise to projects ranging From pre-clinical, clinical, EMA submission, EU medical advisory boards, EU manufacturing and commercial partnerships.